Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal blood test
Susan G. Komen Advocates in Science will provide patient perspective to inform design of research studies and strategies for personalized cancer care. (Credit: Guardant Health)
Guardant Health, a leading precision oncology company, and Susan G. Komen, the world’s leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.
The focus of the partnership will be to support the development of clinical utility data for Guardant Reveal™, a blood test for the detection of minimal residual disease (MRD) in patients with early-stage breast cancer. The test detects circulating tumor DNA (ctDNA) in the blood as a measurement of MRD, the presence of which indicates a high risk for disease recurrence.
A critical element of the partnership is the use of input from patient advocates to guide the research study design. These advocates, who serve as Susan G. Komen Advocates in Science, will provide a first-hand perspective of what matters most to patients with early-stage breast cancer in the development of research to find more effective approaches to their care.
“Susan G. Komen’s partnership with Guardant will help us achieve our goal of conquering deadly and aggressive breast cancers and saving lives by moving us towards personalized treatment through identifying which patients are at higher risk for recurrence,” said Victoria Wolodzko Smart, SVP of Mission at Susan G. Komen. “By involving patient advocates in study design, we can achieve truly patient-centric research, clinical trials and treatment, bringing us closer to the goal of improving care and outcomes for all patients.”
“We’re excited to partner with Susan G. Komen to help ensure a patient-centered approach to research for breast cancer patients,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Leveraging their knowledge and resources will help us accelerate the understanding of the clinical value of MRD monitoring and how to personalize care to the specific needs of each patient with early-stage breast cancer to help improve outcomes.”
Source: Company Press Release